BioCentury | Jan 11, 2019
Clinical News

Contrafect to test S. aureus therapy in Phase III despite Phase II miss

...Exebacase (CF-301) from ContraFect Corp. (NASDAQ:CFRX) plus standard of care (SOC) antibiotics missed the primary endpoint...
...York, N.Y.). ContraFect Corp. (NASDAQ:CFRX), Yonkers, N.Y. The Rockefeller University, New York, N.Y. Product: Exebacase (CF-301...
...Endpoint: Clinical response rate at day 14 Status: Phase II data Milestone: NA Sandi Wong Staphylococcus lysin, exebacase (CF-301) ContraFect...
BioCentury | May 16, 2016
Analyst Picks & Changes

Analyst picks & changes

...$3.30 from $14. He predicts it will be 1.5-2 years before Phase II data from CF-301...
BioCentury | Feb 8, 2016
Clinical News

Staphylococcus lysin: Phase I data

...of IV CF-301 led to no treatment-related adverse effects. ContraFect said its next trial of CF-301...
...patients with Staphylococcus aureus bacteremia, including endocarditis. ContraFect Corp. (NASDAQ:CFRX), Yonkers, N.Y. Product: Staphylococcus lysin ( CF-301...
BioCentury | Aug 24, 2015
Clinical News

Staphylococcus lysin regulatory update

...FDA granted Fast Track designation to ContraFect’s CF-301 to treat Staphylococcus aureus bloodstream infections, including methicillin-resistant...
...including methicillin-resistant S. aureus (MRSA). The company expects to complete a Phase I trial of CF-301...
...lysin protein (see BioCentury, Oct. 3, 2011). ContraFect Corp. (NASDAQ:CFRX), Yonkers, N.Y. Product: Staphylococcus lysin ( CF-301...
BioCentury | Aug 18, 2015
Company News

ContraFect's CF-301 gets Fast Track designation

...NASDAQ:CFRX) gained $0.83 (18%) to $5.39 on Monday after FDA granted Fast Track designation to CF-301...
...a lysin targeting Staphylococcus aureus. ContraFect began a Phase I study in April of CF-301...
BioCentury | Aug 17, 2015
Clinical News

Staphylococcus lysin: Phase I ongoing

...of a double-blind, placebo-controlled, U.S. Phase I trial to evaluate single ascending doses of IV CF-301...
...to CF-301 (see BioCentury, Oct. 3, 2011). ContraFect Corp. (NASDAQ:CFRX), Yonkers, N.Y. Product: Staphylococcus lysin ( CF-301...
BioCentury | May 11, 2015
Clinical News

Staphylococcus lysin: Phase I started

...began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate single ascending doses of IV CF-301...
...to CF-301 (see BioCentury, Oct. 3, 2011). ContraFect Corp. (NASDAQ:CFRX), Yonkers, N.Y. Product: Staphylococcus lysin ( CF-301...
BioCentury | Dec 11, 2014
Targets & Mechanisms

Lysin in wait

...that digest S. aureus are poorly expressed and exhibit low solubility. The company's lead compound, CF-301...
...inoculum that CF-301 provided similar protection to high doses of Cubicin daptomycin. 1 Treatment with CF-301...
...ContraFect CSO Michael Wittekind, the company expects to begin Phase I trials in 2015 evaluating CF-301...
BioCentury | Aug 4, 2014
Finance

Highlights of weekly biotech stock moves

...a class of enzymes called lysins along with combinations of mAbs that target virulence factors. CF-301...
BioCentury | Jul 30, 2014
Financial News

ContraFect raises $36 million in bumped-up IPO

...the cell walls of Gram-positive bacteria, along with combinations of mAbs that target virulence factors. CF-301...
Items per page:
1 - 10 of 21